美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

225.31

+5.362.44%

成交量：27.39万

成交额：6,130.10万

市值：243.46亿

市盈率：-60.84

高：225.97

开：223.88

低：220.87

收：219.95

数据加载中...

总览公司新闻公告

百济神州2024年年报点评：营收大幅增长，2025年将迎来 GAAP经营性利润转正【东吴医药朱国广团

国广有话说

百济神州总裁吴晓滨：将医疗信息进行整合并发现规律，可为人类健康带来巨大福祉

累亏超600亿元！市值却超3600亿元

中国基金报

百济神州胜诉

百济神州5月2日成交额为4631.11万美元

港股医药股走势疲软，百济神州跌近6%

每日经济新闻

两大千亿营收巨头领跑！云南白药首破400亿，百济神州、恒瑞大涨，人福、片仔癀……创新高

百济神州因受限制股份单位获归属发行28.8万股

百济神州(06160)因受限制股份单位获归属发行28.8万股

百济神州BCL-2抑制剂申报上市

百济神州4月30日成交额为9176.79万美元

跨国药企碰瓷失败，百济神州专利保卫战大捷

百济神州参投，可编程 mRNA实现 IL-12瘤内定向激活，开启“mRNA 2.0”

美股异动 | 百济神州(ONC.US)涨逾3% 2024年收入同比增长55%

百济神州在美国专利纠纷中获胜，USPTO裁定相关专利无效

百济神州在美赢得专利诉讼，艾伯维Pharmacyclics公司专利判无效

百济神州：Pharmacyclics诉讼所涉专利被裁定无效

创新药产业链表现良好，百济神州、诺诚健华、恒瑞医药等持续活跃

百济神州“泽布替尼”专利侵权案胜诉

医药魔方Info

回港中概股午后走强，金山云涨超13%，百济神州涨超7%，万国数据涨超6%，宝尊电商、BOSS直聘涨超2%。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ONC/news?page=6"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":225.31,"timestamp":1747337139318,"preClose":219.95,"halted":0,"volume":273893,"delay":0,"floatShares":69370116,"shares":108055817,"eps":-3.70325,"marketStatus":"交易中","change":5.36,"latestTime":"05-15 15:25:53 EDT","open":223.88,"high":225.97,"low":220.865,"amount":61301027.64554,"amplitude":0.02321,"askPrice":225.53,"askSize":102,"bidPrice":225.08,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1747339200000},"marketStatusCode":2,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":219.95,"preHourTrading":{"tag":"盘前","latestPrice":222.8,"preClose":219.95,"latestTime":"09:28 EDT","volume":158,"amount":35194.24878,"timestamp":1747315680073},"postHourTrading":{"tag":"盘后","latestPrice":219.95,"preClose":219.95,"latestTime":"18:20 EDT","volume":1825,"amount":401390.1,"timestamp":1747261215490},"volumeRatio":0.716449,"impliedVol":0.4035,"impliedVolPercentile":0.163},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":69370116,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.716449,"shares":108055817,"dividePrice":0,"high":225.97,"amplitude":0.02321,"preClose":219.95,"low":220.865,"week52Low":141.31,"pbRate":"6.96","psRate":"5.83","week52High":287.88,"institutionHeld":0,"latestPrice":225.31,"committee":-0.961538,"eps":-3.70325,"divideRate":0,"volume":273893,"delay":0,"ttmEps":-3.70325,"open":223.88,"prevYearClose":184.71,"prevWeekClose":231.99,"prevMonthClose":259.81,"prevQuarterClose":272.17,"fiveDayClose":235.94,"twentyDayClose":228.14,"sixtyDayClose":236.69},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533634234","title":"百济神州2024年年报点评：营收大幅增长，2025年将迎来 GAAP经营性利润转正【东吴医药朱国广团","url":"https://stock-news.laohu8.com/highlight/detail?id=2533634234","media":"国广有话说","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533634234?lang=zh_cn&edition=fundamental","pubTime":"2025-05-06 21:30","pubTimestamp":1746538248,"startTime":"0","endTime":"0","summary":"投资要点事件：公司4月底发布2024年年报，公司2024年实现收入272.1亿元，同比+56.2%。归母净利润-49.8亿元，进一步减亏，全年实现非GAAP经营性利润为正。得益于泽布替尼全球销售的快速增长，业绩略 超市 场预期。公司2025年全年收入指引为49亿至53亿美金，GAAP经营性利润转正。泽布替尼全球销售快速增长，BCL2抑制剂和BTK CDAC巩固血液瘤领军地位。泽布替尼目前已在70+市场获批，在美国CLL新患者治疗中处于领先地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506214115a6d51b3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506214115a6d51b3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC"],"gpt_icon":0},{"id":"2533506576","title":"百济神州总裁吴晓滨：将医疗信息进行整合并发现规律，可为人类健康带来巨大福祉","url":"https://stock-news.laohu8.com/highlight/detail?id=2533506576","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533506576?lang=zh_cn&edition=fundamental","pubTime":"2025-05-06 17:20","pubTimestamp":1746523200,"startTime":"0","endTime":"0","summary":"　　4月21日，2025年中国绿公司年会聚焦“医疗健康与生命科学”主题举办高级别闭门研讨。百济神州总裁、首席运营官吴晓滨作题为《创新药的发展与思考》的演讲。　　吴晓滨说，当今无论是发达国家还是发展中国家，有约 80% 的国家所面临的医疗状况与我国十几年前相似——进口药品价格高昂。如果能够整合并结构化处理这些数据，其中蕴含着大量未被发现的生命奥秘和疾病治疗规律，将会对中国人民乃至全人类的健康带来巨大的福祉。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2025-05-06/doc-inevrkva2208050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","LU2328871848.SGD","BK1500","LU0307460666.USD","06160","LU0588546209.SGD","159891","BK1588","BK4139","LU1969619763.USD","BK1161","688235","ONC","BK1583","02197"],"gpt_icon":0},{"id":"2532397845","title":"累亏超600亿元！市值却超3600亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532397845","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532397845?lang=zh_cn&edition=fundamental","pubTime":"2025-05-04 13:59","pubTimestamp":1746338381,"startTime":"0","endTime":"0","summary":"百济神州4月28日晚发布的2024年年报显示，2024年公司亏损49.78亿元，是2024年亏损金额最多的医药上市公司；累计未弥补亏损为626.67亿元。2024年，恒瑞医药实现营业收入279.85亿元，同比增长22.63%；归属于上市公司股东的净利润为63.37亿元，同比增长47.28%。2024年，百利天恒营业收入为58.23亿元、同比增长936.31%；净利润达37.08亿元，同比增长575.02%；毛利率达95.46%，超过贵州茅台的91.93%。文章来源：中国基金报累亏超600亿元！","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250504141916a471a5a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250504141916a471a5a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","688235","06160"],"gpt_icon":0},{"id":"2532360144","title":"百济神州胜诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2532360144","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532360144?lang=zh_cn&edition=fundamental","pubTime":"2025-05-04 10:01","pubTimestamp":1746324060,"startTime":"0","endTime":"0","summary":"百济神州宣布胜诉，USPTO裁定Pharmacyclics的‘803专利无效，该专利是艾伯维子公司对百济神州产品百悦泽®提出的侵权指控的核心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050410061594ebdeda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050410061594ebdeda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160","BK0239"],"gpt_icon":0},{"id":"2532802797","title":"百济神州5月2日成交额为4631.11万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532802797","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532802797?lang=zh_cn&edition=fundamental","pubTime":"2025-05-03 10:17","pubTimestamp":1746238671,"startTime":"0","endTime":"0","summary":"美东时间2025年5月2日，百济神州成交额为4631.11万美元，成交额较昨日减少45.66%，当日成交量为18.04万股。百济神州于2025年5月2日涨0.05%，报255.77美元，该股过去5个交易日涨4.44%，年初至今涨38.47%，过去60日涨12.34%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503101758a6d1a075&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503101758a6d1a075&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2532185122","title":"港股医药股走势疲软，百济神州跌近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532185122","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532185122?lang=zh_cn&edition=fundamental","pubTime":"2025-05-02 09:55","pubTimestamp":1746150915,"startTime":"0","endTime":"0","summary":"港股医药股走势疲软，百济神州跌近6%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505023395436693.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505023395436693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0588546209.SGD","ONC","BK1583","LU2328871848.SGD","06160","BK1161","BK4139","BK1588","LU0307460666.USD","BK1500","LU1969619763.USD"],"gpt_icon":0},{"id":"2532633888","title":"两大千亿营收巨头领跑！云南白药首破400亿，百济神州、恒瑞大涨，人福、片仔癀……创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2532633888","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532633888?lang=zh_cn&edition=fundamental","pubTime":"2025-05-02 08:09","pubTimestamp":1746144552,"startTime":"0","endTime":"0","summary":"从营收增速来看，百济神州、新和成、恒瑞医药、华润三九等5家均有双位数增长；智飞生物跌幅最大，超过50%。上海医药、九州通两家千亿营收龙头继续领跑，重药控股、南京医药、国药股份均超过500亿元。创新高，云南白药首破400亿此外，人福医药、恒瑞医药、科伦药业、片仔癀等超20家创新高。其中，国药股份首次突破500亿元，云南白药首次突破400亿元，百济神州、新和成和鹭燕医药首次突破200亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502114021a46f932b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502114021a46f932b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600436","688235","000538","ONC","600276","06160"],"gpt_icon":0},{"id":"2532071837","title":"百济神州因受限制股份单位获归属发行28.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2532071837","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532071837?lang=zh_cn&edition=fundamental","pubTime":"2025-05-02 07:59","pubTimestamp":1746143940,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　百济神州（06160）发布公告，于2025年4月30日，因根据股权计划授出的受限制股份单位获归属（公司董事除外）而发行28.8万股。\n　　于2025年4月30日，因合资格参与者（公司董事除外）行使购股权而发行合计113.1万股。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-02/doc-inevcpfk0018566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0307460666.USD","LU2328871848.SGD","06160","ONC","BK1161","LU1969619763.USD","BK4139","BK0239","BK1588","LU0588546209.SGD","BK1583","BK1500","688235"],"gpt_icon":0},{"id":"2532377318","title":"百济神州(06160)因受限制股份单位获归属发行28.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2532377318","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532377318?lang=zh_cn&edition=fundamental","pubTime":"2025-05-02 07:49","pubTimestamp":1746143373,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年4月30日，因根据股权计划授出的受限制股份单位获归属(公司董事除外)而发行28.8万股。于2025年4月30日，因合资格参与者(公司董事除外)行使购股权而发行合计113.1万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288843.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0588546209.SGD","BK0239","LU0307460666.USD","LU1969619763.USD","06160","LU2328871848.SGD","BK1588","BK1500","688235","BK4139","BK1583","ONC","BK1161"],"gpt_icon":0},{"id":"2532886091","title":"百济神州BCL-2抑制剂申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2532886091","media":"医药地理","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532886091?lang=zh_cn&edition=fundamental","pubTime":"2025-05-01 17:22","pubTimestamp":1746091342,"startTime":"0","endTime":"0","summary":"4月28日，国家药品监督管理局药品审评中心网站显示，百济神州的索托克拉片申报上市。索托克拉是百济神州开发的一款强效、高选择性BCL-2抑制剂，其设计旨在产生更深、更持久的靶点抑制。根据百济神州介绍，与维奈克拉相比，索托克拉在临床前研究和肿瘤模型中均显示出更高的效力和靶点选择性，并有可能克服耐药性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502013623a6d04148&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502013623a6d04148&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2532487660","title":"百济神州4月30日成交额为9176.79万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532487660","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532487660?lang=zh_cn&edition=fundamental","pubTime":"2025-05-01 10:18","pubTimestamp":1746065913,"startTime":"0","endTime":"0","summary":"美东时间2025年4月30日，百济神州成交额为9176.79万美元，成交额较昨日增加14.81%，当日成交量为35.31万股。百济神州于2025年4月30日涨4.02%，报259.81美元，该股过去5个交易日涨4.29%，年初至今涨40.66%，过去60日涨16.31%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501101837a6cf90a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501101837a6cf90a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2532704819","title":"跨国药企碰瓷失败，百济神州专利保卫战大捷","url":"https://stock-news.laohu8.com/highlight/detail?id=2532704819","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532704819?lang=zh_cn&edition=fundamental","pubTime":"2025-05-01 07:30","pubTimestamp":1746055845,"startTime":"0","endTime":"0","summary":"2025年4月29日，美国专利商标局作出了一项最终书面决定，宣布艾伯维旗下的Pharmacyclics公司在803专利授权后复审程序中受到质疑的803专利的全部权利无效。在2023年6月13日，Pharmacyclics公司作为申诉方，在美国特拉华州地方法院，对百济神州及其全资子公司BeOne Medicines USA提出申诉。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501104311a6cf956b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501104311a6cf956b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688235","BK0239","06160"],"gpt_icon":0},{"id":"2532101739","title":"百济神州参投，可编程 mRNA实现 IL-12瘤内定向激活，开启“mRNA 2.0”","url":"https://stock-news.laohu8.com/highlight/detail?id=2532101739","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532101739?lang=zh_cn&edition=fundamental","pubTime":"2025-05-01 07:21","pubTimestamp":1746055260,"startTime":"0","endTime":"0","summary":"Strand Therapeutics展示了一种可编程mRNA疗法STX-003，能精准调控IL-12在肿瘤组织的表达，提高耐受性并维持抗肿瘤疗效，其核心优势在于自复制mRNA与遗传电路的结合，为肿瘤治疗提供创新策略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501094317974c26cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501094317974c26cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","688235","BK1500","LU1969619763.USD","LU0307460666.USD","LU2328871848.SGD","ONC","BK1161","06160","BK1588","BK1583"],"gpt_icon":0},{"id":"2531205560","title":"美股异动 | 百济神州(ONC.US)涨逾3% 2024年收入同比增长55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531205560","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531205560?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 21:59","pubTimestamp":1746021564,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，百济神州涨逾3%，报259美元。财报显示，百济神州2024年实现收入合计约38.1亿美元，同比增长约55%；产品收入同比增长约72.6%至约38亿美元。4月30日早间，百济神州公告，美国专利商标局作出了一项最终书面决定，宣布Pharmacyclics在‘803 专利授权后复审程序中受到公司质疑的‘803 专利的全部权利无效。Pharmacyclics可对USPTO的最终书面决定提起上诉。公司表示，百悦泽是其原研药品，公司将对此类专利侵权指控进行坚决的辩护。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","688235","LU0307460666.USD","LU1969619763.USD","LU2328871848.SGD","ONC","BK1161","BK1588","BK1500","BK1583","LU0588546209.SGD","BK0239","06160"],"gpt_icon":0},{"id":"2531031201","title":"百济神州在美国专利纠纷中获胜，USPTO裁定相关专利无效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031201","media":"新浪财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031201?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 20:10","pubTimestamp":1746015004,"startTime":"0","endTime":"0","summary":"4月30日，百济神州公告表示，美国专利商标局近日作出决定，宣告Pharmacyclics公司持有的第11672803号美国专利全部权利要求无效。这一裁定源于百济神州及其美国子公司与Pharmacyclics之间的一场专利纠纷。面对指控，百济神州迅速作出反应，于2023年11月向USPTO提交专利授权后复审申请，对“803专利”的合法性提出质疑。同时，法院也暂缓了侵权诉讼的审理，以待USPTO的裁决结果。基于以上理由，USPTO最终裁定“803专利”全部权利要求无效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430201652974b8dd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430201652974b8dd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","BK0239","ONC"],"gpt_icon":0},{"id":"2531087307","title":"百济神州在美赢得专利诉讼，艾伯维Pharmacyclics公司专利判无效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531087307","media":"财经涂鸦","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531087307?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 14:52","pubTimestamp":1745995963,"startTime":"0","endTime":"0","summary":"“诉讼目前未对百悦泽在美国的研发和销售产生不利影响。”此前，2023年6月13日，Pharmacyclics向美国特拉华州地方法院提起诉讼，指控百济神州及其全资子公司相关活动导致百悦泽对其“803专利”造成侵权。而泽布替尼与艾伯维/Pharmacyclics重磅药物依布替尼同属BTK抑制剂系列，两款产品有直接竞争关系。Pharmacyclics可对USPTO的最终书面决定提起上诉。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043015171594e89cd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043015171594e89cd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","ABBV","BK0239","688235"],"gpt_icon":0},{"id":"2531056717","title":"百济神州：Pharmacyclics诉讼所涉专利被裁定无效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531056717","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531056717?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 14:16","pubTimestamp":1745993763,"startTime":"0","endTime":"0","summary":"中新经纬4月30日电 30日早间，百济神州发布一则涉及诉讼的公告。该诉讼起源于2023年6月，美国生物制药公司艾伯维旗下的Pharmacyclics公司指控百济神州的药物泽布替尼侵犯专利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430153826974b3fdd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430153826974b3fdd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","ONC","06160","688235"],"gpt_icon":0},{"id":"2531722937","title":"创新药产业链表现良好，百济神州、诺诚健华、恒瑞医药等持续活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2531722937","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531722937?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 14:14","pubTimestamp":1745993640,"startTime":"0","endTime":"0","summary":"创新药产业链表现强劲，多家企业如百济神州、诺诚健华和恒瑞医药等持续活跃。百济神州2024年营收同比增长56.19%，核心产品泽布替尼和替雷利珠单抗收入显著增长，预计2025年实现全年经营利润为正。诺诚健华的BCL2抑制剂ICP-248片拟纳入突破性治疗品种，奥布替尼新适应症获批用于一线治疗CLL/SLL。锦波生物2024年营收同比增长84.92%。机构看好创新药产业链在2024年的持续良好表现，认为医药行业将迎来结构性机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142522974b2a83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142522974b2a83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0405327148.USD","BK0060","06160","BK0183","BK0012","BK0188","LU1064131003.USD","LU2488822045.USD","LU1064130708.USD","LU1328615791.USD","ONC","BK0028","LU0405327494.USD","600276","BK0239","LU2148510915.USD","09969","LU1969619763.USD","688235","688428","159992","BK0196","LU2328871848.SGD"],"gpt_icon":0},{"id":"2531708753","title":"百济神州“泽布替尼”专利侵权案胜诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2531708753","media":"医药魔方Info","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531708753?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 13:59","pubTimestamp":1745992799,"startTime":"0","endTime":"0","summary":"4月30日，百济神州宣布，美国专利商标局（USPTO）作出了一项最终书面决定，宣布艾伯维旗下Pharmacyclics LLC在专利授权后复审（PGR）程序中受到百济神州质疑的第11672803号美国专利（‘803专利）的全部权利无效。Pharmacyclics可对USPTO的最终书面决定提出上诉。该诉讼经过如下：2023年6月15日，Pharmacyclics指控百济神州BTK抑制剂百悦泽（泽布","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430152124a6ce73a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430152124a6ce73a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160","BK0239"],"gpt_icon":0},{"id":"2531377644","title":"回港中概股午后走强，金山云涨超13%，百济神州涨超7%，万国数据涨超6%，宝尊电商、BOSS直聘涨超2%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531377644","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531377644?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 13:36","pubTimestamp":1745991360,"startTime":"0","endTime":"0","summary":"回港中概股午后走强，金山云涨超13%，百济神州涨超7%，万国数据涨超6%，宝尊电商、BOSS直聘涨超2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/30133650037219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06160","BK1586","BK1613","BK4531","BK4614","BK4505","BK4502","BK1588","BK4607","BK1517","BZ","03888","09698","TTTN","688235","ONC","LU0307460666.USD","BK1589","BK1607","LU1023057109.AUD","BK4509","LU0359201612.USD","BK4122","BK1518","LU2039709279.SGD","BK1500","BK1583","LU0348766576.USD","BK4585","BK4077","LU1688375341.USD","BK4220","BK4551","LU0359202008.SGD","BK0239","BK4563","BK4503","GDS","BK4608","BK1585","LU0588546209.SGD","LU0348767384.USD","LU1969619763.USD","BK1526","BZUN","BK1575","BK4588","BK1134"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盘前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-05-14","current":-61.889623,"percent":0.044944,"low":-64.911375,"twenty":-43.424174,"median":-39.182934,"eighty":-28.820246,"high":-22.805663,"avg":-37.41726,"sd":9.466346,"marketCap":24283383754},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794},{"date":"2025-04-11","current":-34.741183,"twenty":-42.946887,"median":-33.164233,"eighty":-28.695114,"marketCap":22400628140},{"date":"2025-04-17","current":-38.113584,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"marketCap":24575105056},{"date":"2025-04-25","current":-42.900785,"twenty":-42.748137,"median":-34.741183,"eighty":-28.796727,"marketCap":27661825682},{"date":"2025-05-02","current":-42.724352,"twenty":-42.75242,"median":-37.447221,"eighty":-28.798247,"marketCap":27548064220},{"date":"2025-05-09","current":-64.911375,"twenty":-42.880619,"median":-38.484462,"eighty":-28.804303,"marketCap":25469016595},{"date":"2025-05-14","current":-61.889623,"twenty":-43.424174,"median":-39.182934,"eighty":-28.820246,"marketCap":24283383754}],"updateTime":1747327376649}}}